What is KPV?
KPV stands for lysine–proline–valine (Lys-Pro-Val). It is a tripeptide — a chain of just three amino acids — that comes from the C-terminal (tail) end of alpha-melanocyte-stimulating hormone (α-MSH).
Alpha-MSH is a naturally occurring hormone with roles in pigmentation, appetite, and inflammation. Researchers noticed that the last three amino acids at the end of α-MSH retain much of the hormone's anti-inflammatory activity on their own. That fragment is KPV.
The idea is that a small, stable tripeptide might be easier to deliver into tissues — especially the gut — than the full hormone. Most KPV research focuses on whether it can reach immune cells in the intestinal wall and quiet inflammatory signals there.
KPV is not a hormone replacement and it is not FDA-approved for any use. All human-use claims currently rest on cell-culture and mouse-model data.
Is KPV FDA-Approved?
No. KPV is not approved by the U.S. Food and Drug Administration for any indication. There is no NDA, BLA, or 510(k) clearance for KPV.
KPV does not appear on the FDA's list of approved drug products (the Orange Book) or the Purple Book (biologics). It is also not in the FDA's 503B outsourcing facility bulk drug substance list as of this writing — which means it is not eligible for large-scale compounding for office-use distribution.
Some 503A compounding pharmacies prepare KPV products on a patient-specific prescription basis. The compound falls in a regulatory gray area: because it is not on any FDA bulk substance nominee list with a final positive determination, its compounded use rests on individual pharmacist and prescriber judgment, not on an approved framework.
If you see KPV marketed with specific dosing instructions or health claims online, those sources are not citing FDA-cleared evidence. They are referencing preclinical research and extrapolating to humans without trial data to back it up.
What Does the Research Show?
Published KPV studies fall into two categories: cell-culture experiments (in vitro) and mouse-model experiments (in vivo). No published Phase 1 or Phase 2 human clinical trials exist as of the date of this article.
In cell-culture studies, KPV has been shown to suppress pro-inflammatory cytokines — signaling proteins that drive swelling and tissue damage — in colon epithelial and immune cells. The proposed mechanism involves binding to the melanocortin-1 receptor (MC1R) and blocking the NF-κB signaling pathway, a central switch in the inflammatory response.
In mouse models of colitis (typically induced by dextran sodium sulfate, or DSS), KPV reduced markers of gut inflammation. A key research challenge is delivery: short peptides are digested in the stomach before they can reach the colon. Several groups have tested oral nanoparticle formulations — packaging KPV in a tiny carrier that survives stomach acid — and shown improved delivery to colon tissue in rodents.
These are promising early signals. But mouse colitis models do not map cleanly onto human inflammatory bowel disease. And the doses used in animal studies cannot be converted directly to human doses without safety and pharmacokinetic trials that have not yet been conducted.
Why There Is No Established Human Dose
Every dosing figure for KPV that circulates online traces back to preclinical data. The problem with applying those numbers to humans is fundamental: animal-to-human dose scaling requires knowledge of how a compound is absorbed, distributed, metabolized, and excreted in humans. That data does not exist for KPV.
Standard dose-scaling methods (such as body surface area normalization) can generate a rough starting estimate, but they carry wide uncertainty for compounds with no human pharmacokinetic profile. They are a tool for trial designers to pick a Phase 1 starting dose for a human safety study — not a guide for personal use.
The route of administration also matters enormously. Most KPV animal studies use oral nanoparticle delivery, direct intracolonic instillation, or intraperitoneal injection. None of these match the subcutaneous injection route that most compounding protocols use, which means bioavailability data from the animal studies does not translate.
| Category | Status | What it means for dosing |
|---|---|---|
| Cell-culture (in vitro) | Multiple studies published | Shows mechanism; no dose information for whole organisms |
| Animal models (in vivo) | Multiple murine colitis studies | Doses in mg/kg; route mismatch with human SC use |
| Human Phase 1 (safety) | None published | No human pharmacokinetics; no safety dose range established |
| Human Phase 2 (efficacy) | None published | No efficacy benchmark in humans exists |
| FDA approval | Not approved | No approved indication, labeling, or dosing guidance |
What Clinicians Consider When KPV Is in a Protocol
Despite the absence of human trials, some integrative and functional medicine clinicians include KPV in multi-peptide protocols for patients with inflammatory gut conditions. When they do, their approach is extrapolation from the preclinical literature combined with clinical judgment — not evidence-based dosing in the usual sense.
Clinicians who work with investigational peptides typically start at the lowest plausible dose, monitor for tolerability, and adjust based on symptom response and biomarker changes rather than a fixed protocol. They also consider the patient's full picture: concurrent medications, underlying conditions, and which part of the gut is affected.
If a clinician is prescribing KPV, they should also be ordering baseline and follow-up markers. For gut inflammation, that might include calprotectin, CRP, or standard IBD panels depending on the clinical question. Tracking those numbers over time is the only way to distinguish a real response from a placebo effect or natural disease fluctuation.
KPV is almost always combined with other compounds (BPC-157, for example, often appears in the same protocols). When multiple investigational peptides are used together, attributing any outcome — positive or negative — to KPV specifically becomes very difficult.
Where the KPV Evidence Actually Comes From
It is worth being specific about the studies people are citing, because "the research shows" is doing a lot of unearned work in most KPV marketing. The literature is real, but it is narrow, and almost none of it involves giving KPV to a person.
The foundational paper is from 1984. Richards and Lipton, publishing in Peptides, tested whether the last three amino acids of alpha-MSH — positions 11 to 13, which is lysine-proline-valine — carried the fever-reducing effect of the whole hormone. Longer fragments such as alpha-MSH 1-10 had done nothing. KPV, given both centrally and peripherally, did. That is the origin of the entire field: a rabbit fever model, forty years ago, establishing that the tripeptide is the active tail.
The mechanistic work most often cited is Land (2012), in cultured human bronchial epithelial cells. That study examined how KPV suppresses inflammatory chemokine signalling and implicated melanocortin receptor 3. It is genuinely human tissue — but it is cells in a dish, exposed to a known concentration in culture medium. A concentration in a well is not a dose in a body, and the paper does not claim otherwise.
More recent work is largely about delivery rather than dosing. Shao and colleagues (2021) built a mucoadhesive hydrogel to hold KPV against inflamed oral tissue in chemotherapy-induced mucositis. The interesting variable there is the carrier, not the quantity. Gravina and colleagues (2023) reviewed the melanocortin system in inflammatory bowel disease, placing KPV within a broader signalling pathway that also includes the full hormone and other fragments.
Read together, the pattern is consistent: a well-characterised anti-inflammatory signal, demonstrated in animals and in cultured cells, with active research into how you would even deliver it. What is missing is the step everything else depends on — a human trial that administers a defined amount and measures what happens.
Why Delivery, Not Dose, Is the Live Research Question
If you follow the KPV literature forward from 1984, the striking thing is what researchers spend their effort on. It is not finding the right number of milligrams. It is getting the molecule to the tissue at all.
The problem is that KPV is three amino acids long. That is what makes it interesting — small, stable, potentially able to slip into tissues the parent hormone cannot reach — and it is also what makes it fragile. Swallow a tripeptide and the stomach and small intestine will treat it as food. Digestive proteases break peptide bonds; that is their function. The molecule is largely dismantled before it reaches the colon, which is precisely where gut-inflammation research wants it.
This is why so much KPV work involves a vehicle rather than a syringe. Hydrogels that adhere to inflamed mucosa. Nanoparticle encapsulation intended to survive the upper gut. Formulations that exploit PepT1, a peptide transporter that is upregulated in inflamed intestinal tissue and can carry small peptides across the epithelium. Each of these is an attempt to answer "how does it get there", not "how much".
The practical consequence matters for anyone reading a dosing figure online. A quantity is meaningless without the route and the formulation attached to it. An amount delivered intracolonically in a mouse, an amount encapsulated in a nanoparticle, and an amount injected subcutaneously in a person are not interchangeable numbers, even if the milligram figure happens to look similar. Bioavailability — the fraction that actually reaches the target intact — differs by orders of magnitude between them.
So when a protocol specifies a KPV dose without specifying the formulation, the delivery route, and what evidence links that route to a measured tissue concentration, the number is closer to a guess wearing a lab coat than a finding.
How to Read a KPV Dosing Number You Find Online
Most KPV dosing figures circulating on forums and vendor sites trace back to animal experiments, usually expressed in milligrams per kilogram of body weight. Converting one of those into a human dose is not a matter of multiplying by body weight, though that is exactly what many online calculators do.
Species differ in metabolic rate, clearance, and body-surface-area-to-mass ratio. Regulatory science uses allometric scaling — body surface area rather than raw weight — precisely because a straight mg/kg conversion from a mouse systematically overestimates the human equivalent, often by a factor of around twelve. A figure derived by simple multiplication is not conservative; it is wrong in the direction of too much.
Even a correctly scaled figure is only a starting point for designing a first-in-human safety study, not a treatment dose. That is what phase 1 trials exist to establish, and KPV has not been through one.
A reasonable way to evaluate any KPV dosing claim you encounter: does the source name the study it came from? Does it state the species, the route, and the formulation? Does it distinguish between a concentration used in cell culture and an amount administered to an animal? If the answer to those is no, the number has been detached from everything that gave it meaning.
None of this means KPV is worthless or that the research is bad. It means the honest description of the current state is "promising preclinical signal, unresolved delivery problem, no human dosing data" — and any number presented with more confidence than that is overstating what is known.
Risks and Unknowns
Because no human trials have been completed, the side-effect and safety profile of KPV in humans is genuinely unknown. The preclinical literature did not identify acute toxicity at study doses in mice, but rodent toxicology does not guarantee human safety.
Short peptides can be immunogenic — they can prompt an immune response — though this risk varies by sequence and formulation. Without immunogenicity data from human subjects, the risk cannot be quantified.
Quality and sterility of compounded KPV vary by pharmacy. Because there is no FDA-approved product to compare against, there is no standard specification for purity, potency, or sterile preparation. Selecting a pharmacy that follows USP <797> sterile compounding standards and performs third-party potency and sterility testing is the minimum quality bar.
Financial risk is also real. Without proven human efficacy, there is no guarantee of benefit. Costs for investigational peptide protocols can run into hundreds of dollars per month, and insurance will not cover a compound with no approved indication.
How PeptidePanel Helps You Track a KPV Protocol
PeptidePanel does not recommend specific peptides, doses, or protocols — that is your clinician's job. What PeptidePanel does is give you a structured place to log what your clinician has prescribed, track your dose and schedule, and record how you feel over time.
When you are on an investigational compound like KPV, having a clear record matters. You can log the compound, the dose, the start date, and your biomarker results in one place. If your clinician adjusts the protocol, you have a timeline that shows what changed and when — which is far more useful than trying to reconstruct the history from memory.
If you are working with a clinician on a gut-focused protocol that includes KPV, PeptidePanel can help you stay organized and bring meaningful data to your follow-up appointments.